Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
ZAI LAB(ZLAB) Businesswire·2024-03-07 05:01ZAI LAB(ZLAB) Businesswire·2024-03-07 05:01
R1ZAI LAB(ZLAB) Businesswire·2024-03-07 05:01